leadf
logo-loader
viewIXICO PLC

IXICO lands £3.4mln trial contract

The company will provide operational services and advanced AI neuroimaging expertise

IXICO PLC -

IXICO PLC (LON:IXI), the AI data analytics company focused on neuroscience, has landed a four-and-a-half-year contract worth £3.4mln.

It is with an existing client working on a trial of a drug for the rare neurodegenerative condition Spinocerebellar Ataxia type 3 (SCA3), also known as Machado-Joseph disease.

Currently, there is no treatment to slow down or reverse the progressive course of this terminal condition.

"SCA3 is an area with clear, unmet medical needs and we are delighted to be chosen as the neuroimaging partner in this spinocerebellar ataxia trial,” said IXICO chief commercial officer Lammert Albers in a statement.

The company will provide operational services and advanced AI neuroimaging for volumetric, diffusion and functional magnetic resonance as well as magnetic resonance spectroscopy and quantitative susceptibility mapping.

“Neuroimaging, with its unique ability to reveal extraordinary information about the structural and functional characteristics of the human brain is a powerful tool in CNS studies, and we are proud to support our clients in potentially unlocking new insights into disease progression," added Albers.

Quick facts: IXICO PLC

Price: 88 GBX

AIM:IXI
Market: AIM
Market Cap: £41.62 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of IXICO PLC named herein, including the promotion by the Company of IXICO PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Market Report: Brexit bells set to ring this Christmas Eve

The market report with Katie Pilbeam. FTSE 100 headed to the Christmas break in good cheer on the growing possibility that a Brexit deal will be announced today. The news overshadowed reports of another mutant coronavirus strain and helped London’s blue-chip index rise 19 to 6,515. Yes,...

on 24/12/20

2 min read